SCNLF Projected Dividend Yield

Scancell Holdings PLC ( OTCBB : SCNLF )

Scancell Holdings is engaged in the discovery and development of novel vaccines for the treatment of cancer based on its immunotherapy platforms, ImmunoBody® and Moditope®. ImmunoBody® platform uses the body's immune system to identify, attack and destroy tumors. It consists of SCIB1 vaccine for treatment of metastatic melanoma; and SCIB2 vaccine for treatment of non-small cell lung cancer and other solid tumors. Moditope® is a platform that targets tumor associated stress-induced post-translational modifications. It includes Modi-1 vaccine for treatment of breast cancer, ovarian cancer, head and neck cancer, and other cancers; and Modi-2 vaccine for treatment of solid cancers.

20 YEAR PERFORMANCE RESULTS